[ad_1]
<img src = "https://www.marketbeat.com/logos/mediwound-ltd-logo.jpg" alt = "Mediwound (NASDAQ: MDWD) was downgraded by Zacks Investment Research from a note of "hold" to a note of "sell" in According to Zacks, "MediWound Ltd. is a niche company specializing in biotechnology that is dedicated to the development, manufacture and marketing of products to meet needs. unmet in the areas of severe burn and chronic wounds management.The company also develops NexoBrid for the removal of pressure sore, dead or damaged tissue in adults with partial and deep thermal burns Deep MediWound Ltd. is based in Yavne, Israel. "
Other badysts also published reports ValuEngine has updated Mediwound shares from a" sell "rating to a rating of" conservation "in a report on Friday, June 1, 2010. Oppenheime r set a target price of $ 14.00 on Mediwound shares in a report on Monday, June 11th. Finally, Wells Fargo & Co reiterated a "buy" rating on Mediwound shares in a report on Tuesday May 29th. An badyst rated the stock with a sales note, one badigned a reserve rating and five issued a buy-to-action note. Mediwound currently has a consensual rating of "Buy" and an average price target of $ 9.29.
Mediwound fell $ 0.20 to $ 6.25 Wednesday, according to Marketbeat. The company had a trading volume of 76,713 shares, compared to its average volume of 32,132. The company has a market capitalization of $ 181.22 million, a price / earnings ratio of -10.08 and a beta of -0.09. Mediwound has a 12 month low of $ 3.56 and a high of $ 12.50 in 12 months.
Mediwound (NASDAQ: MDWD) last announced its quarterly results on Thursday, May 10. The biopharmaceutical company reported ($ 0.17) earnings per share (EPS) for the quarter, in line with badysts' consensus ($ 0.17). The company achieved a sales turnover of $ 0.52 million for the quarter, compared to a consensus estimate of $ 0.57 million. Mediwound posted a negative net margin of 904.12% and a negative return on equity of 226.62%. stock badysts expect Mediwound to post earnings per share of -0.76 for the current year.
Several major investors have recently changed their holdings of MDWD. Renaissance Technologies LLC increased its stake in Mediwound shares by 18.2% in the fourth quarter. Renaissance Technologies LLC now holds 100,600 shares in the $ 448,000 biopharmaceutical company after purchasing an additional 15,500 shares in the last quarter. Wells Fargo & Company MN increased its stake in Mediwound shares by 84.6% in the fourth quarter. Wells Fargo & Company MN now holds 101,189 biopharmaceutical company shares worth $ 450,000 after purchasing an additional 46,366 shares in the last quarter. Finally, Meitav Dash Investments Ltd. purchased a new position in Mediwound shares in the fourth quarter valued at $ 2,184,000. 32.78% of the capital is held by institutional investors and hedge funds.
About Mediwound
MediWound Ltd., an integrated biopharmaceutical company, focuses on the development, manufacture and commercialization of novel therapeutics to address unmet needs. It markets NexoBrid, a biopharmaceutical product aimed at eliminating bedsores, dead or damaged tissue in adults with partial or total deep thermal burns in the European Union, Israel and Argentina. .
Zacks Research Report on Mediwound (MDWD)
For more information on Zacks Investment Research's research offerings, visit Zacks.com
Receive news and ratings of Mediwound Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Mediwound and related companies with MarketBeat. com electronic newsletter.
Source link
